Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 145
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 
     
This article has been cited by
1Alkyl and Aryl Derivatives Based on p-Coumaric Acid Modification and Inhibitory Action against Leishmania braziliensis and Plasmodium falciparum
Susiany P. Lopes,Lina M. Yepes,Yunierkis Pérez-Castillo,Sara M. Robledo,Damião P. de Sousa
Molecules.2020;25(14)3178
[DOI]
2Case Report: No Response to Liposomal Daunorubicin in a Patient with Drug-Resistant HIV-Associated Visceral Leishmaniasis
Nicholas J. Gow,Robert N. Davidson,Rob Ticehurst,Andrew Burns,Mark G. Thomas,Carlos Franco-Paredes
PLOS Neglected Tropical Diseases.2015;9(8)e0003983
[DOI]
3Promising antileishmanial effectiveness of doxorubicin and Doxil against Leishmania major : An in vitro assay
Azar Shokri,Javad Akhtari,Masoud Keighobadi,Mahdi Fakhar,Saeed Hosseini Teshnizi,Saeed Emami,Sajede Sadjjadian
Asian Pacific Journal of Tropical Medicine.2017;10(6)544
[DOI]
  Feedback 
  Subscribe